secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001493152-24-044160
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026
-------------------------------------------------------------------------

- Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.
- Revenue fell to $0.4M from $1.8M due to PUR1900 wind down; R&D expenses cut 80% to $0.8M.
- Cash and equivalents $10.8M; company expects funding into Q4 2026.
- Completed wind down of PUR1900 Phase 2b; no further financial obligation, to receive 2% royalties ex-US.
- Closed MannKind cross-license for iSPERSE technology; pursuing strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224044160/0001493152-24-044160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224044160/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer